Pretraga

Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1260340

Positive HER3 could be a marker of poor response to neoadjuvant dual anti-HER2 therapy in breast cancer

Ramić, Snježana; Perić Balja, Melita; Veliki Dalić, Irena; Milković Periša, Marija; Orešic, Tomislav; Milas, Ivan
Positive HER3 could be a marker of poor response to neoadjuvant dual anti-HER2 therapy in breast cancer // The Breast THE BREAST, POSTER ABSTRACTS I NEOADJUVANT (PRE- OPERATIVE) THERAPY
Beč, Austrija, 2019. str. S77-S77 doi:10.1016/S0960-9776(19)30280-2 (poster, međunarodna recenzija, sažetak, znanstveni)

CROSBI ID: 1260340 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Positive HER3 could be a marker of poor response to neoadjuvant dual anti-HER2 therapy in breast cancer

Autori
Ramić, Snježana ; Perić Balja, Melita ; Veliki Dalić, Irena ; Milković Periša, Marija ; Orešic, Tomislav ; Milas, Ivan

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
The Breast THE BREAST, POSTER ABSTRACTS I NEOADJUVANT (PRE- OPERATIVE) THERAPY / - , 2019, S77-S77

Skup
16th St. Gallen International Breast Cancer Conference

Mjesto i datum
Beč, Austrija, 19.03.2019. - 21.03.2019

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Breast cancer, human epidermal growth factor receptor 2 (HER2) , neoadjuvant therapy, HER3

Sažetak
Breast cancer patients with over expressed human epidermal growth factor receptor 2 (HER2) recive dual anti-HER2 blockade with trastuzumab and pertuzumab in the neoadjuvant therapy. According to published literature, HER3 can mediate resistance to anti-HER2 therapy. The aim was to search for predictive factors of anti-HER2 neoadjuvant therapy. Poorer response to anti-HER2 therapy in HER3 positive breast cancer patients suggests a possibility for a new treatment option with directed anti-HER3 therapy.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti

Napomena
16th St. Gallen International Breast Cancer
Conference



POVEZANOST RADA

Ustanove:
Klinika za tumore

Profili:

Avatar Url Snježana Ramić (autor)

Avatar Url Marija Milković Periša (autor)

Avatar Url Melita Perić Balja (autor)

Avatar Url Ivan Milas (autor)

Poveznice na cjeloviti tekst rada:

doi www.thebreastonline.com

Citiraj ovu publikaciju:

Ramić, Snježana; Perić Balja, Melita; Veliki Dalić, Irena; Milković Periša, Marija; Orešic, Tomislav; Milas, Ivan
Positive HER3 could be a marker of poor response to neoadjuvant dual anti-HER2 therapy in breast cancer // The Breast THE BREAST, POSTER ABSTRACTS I NEOADJUVANT (PRE- OPERATIVE) THERAPY
Beč, Austrija, 2019. str. S77-S77 doi:10.1016/S0960-9776(19)30280-2 (poster, međunarodna recenzija, sažetak, znanstveni)
Ramić, S., Perić Balja, M., Veliki Dalić, I., Milković Periša, M., Orešic, T. & Milas, I. (2019) Positive HER3 could be a marker of poor response to neoadjuvant dual anti-HER2 therapy in breast cancer. U: The Breast THE BREAST, POSTER ABSTRACTS I NEOADJUVANT (PRE- OPERATIVE) THERAPY doi:10.1016/S0960-9776(19)30280-2.
@article{article, author = {Rami\'{c}, Snje\v{z}ana and Peri\'{c} Balja, Melita and Veliki Dali\'{c}, Irena and Milkovi\'{c} Peri\v{s}a, Marija and Ore\v{s}ic, Tomislav and Milas, Ivan}, year = {2019}, pages = {S77-S77}, DOI = {10.1016/S0960-9776(19)30280-2}, keywords = {Breast cancer, human epidermal growth factor receptor 2 (HER2) , neoadjuvant therapy, HER3}, doi = {10.1016/S0960-9776(19)30280-2}, title = {Positive HER3 could be a marker of poor response to neoadjuvant dual anti-HER2 therapy in breast cancer}, keyword = {Breast cancer, human epidermal growth factor receptor 2 (HER2) , neoadjuvant therapy, HER3}, publisherplace = {Be\v{c}, Austrija} }
@article{article, author = {Rami\'{c}, Snje\v{z}ana and Peri\'{c} Balja, Melita and Veliki Dali\'{c}, Irena and Milkovi\'{c} Peri\v{s}a, Marija and Ore\v{s}ic, Tomislav and Milas, Ivan}, year = {2019}, pages = {S77-S77}, DOI = {10.1016/S0960-9776(19)30280-2}, keywords = {Breast cancer, human epidermal growth factor receptor 2 (HER2) , neoadjuvant therapy, HER3}, doi = {10.1016/S0960-9776(19)30280-2}, title = {Positive HER3 could be a marker of poor response to neoadjuvant dual anti-HER2 therapy in breast cancer}, keyword = {Breast cancer, human epidermal growth factor receptor 2 (HER2) , neoadjuvant therapy, HER3}, publisherplace = {Be\v{c}, Austrija} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE

Citati:

    Altmetrijski pokazatelji:


    Podijeli:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font
    CROSBI koristi kolačiće (cookies) kako bi poboljšao funkcionalnost stranice.